Whole-body galactose oxidation as a robust functional assay to assess the efficacy of gene-based therapies in a mouse model of Galactosemia.
adeno-associated viral vectors
breath test
classic galactosemia
galactose oxidation
gene therapy
lipid nanoparticles
mRNA-based therapy
Journal
Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
received:
13
09
2023
accepted:
12
01
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
epublish
Résumé
Despite the implementation of lifesaving newborn screening programs and a galactose-restricted diet, many patients with classic galactosemia develop long-term debilitating neurological deficits and primary ovarian insufficiency. Previously, we showed that the administration of human
Identifiants
pubmed: 38352271
doi: 10.1016/j.omtm.2024.101191
pii: S2329-0501(24)00007-X
pmc: PMC10863324
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101191Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
The authors declare the following competing interests: X.Y., F.W., J.T., L.C., R.D., S.C., S.M., Y.W., M.Z., J.S., P.G.V.M., and P.F.F. are employees of Moderna and hold equities from the company.